These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 15352709)

  • 1. [New evaluation by the EU approval committee. Benefits of cox-2 inhibitors outweigh possible risks (interview by Dr. Thomas Meissner)].
    Brune K
    MMW Fortschr Med; 2004 Feb; 146(9):47. PubMed ID: 15352709
    [No Abstract]   [Full Text] [Related]  

  • 2. Painful lessons.
    Nat Rev Drug Discov; 2005 Oct; 4(10):800-3. PubMed ID: 16237842
    [No Abstract]   [Full Text] [Related]  

  • 3. [Alleviating pain and preventing inflammation with selective COX-2 inhibitors. Prescribing with confidence in the future].
    MMW Fortschr Med; 2005 Mar; 147(9):12. PubMed ID: 15794346
    [No Abstract]   [Full Text] [Related]  

  • 4. New COX-2 arthritis drug receives FDA approval.
    J Gend Specif Med; 2002; 5(2):6. PubMed ID: 11974679
    [No Abstract]   [Full Text] [Related]  

  • 5. Under surveillance.
    Nat Biotechnol; 2005 Jan; 23(1):1. PubMed ID: 15637596
    [No Abstract]   [Full Text] [Related]  

  • 6. Etoricoxib: new drug. Avoid using cox-2 inhibitors for pain.
    Prescrire Int; 2007 Dec; 16(92):223-7. PubMed ID: 18084859
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular risk and COX-2 inhibition in rheumatological practice.
    Justice E; Carruthers DM
    J Hum Hypertens; 2005 Jan; 19(1):1-5. PubMed ID: 15385947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rofecoxib, Merck, and the FDA.
    Villalba L; Witter J
    N Engl J Med; 2004 Dec; 351(27):2875-8; author reply 2875-8. PubMed ID: 15625745
    [No Abstract]   [Full Text] [Related]  

  • 9. [Overestimated].
    Höer A; Häussler B
    Med Klin (Munich); 2006 Aug; 101(8):676-7; author reply 678-9. PubMed ID: 17051671
    [No Abstract]   [Full Text] [Related]  

  • 10. [Selective cox-2 inhibitors. Better tolerance than NSAID plus antacid].
    MMW Fortschr Med; 2004 Apr; 146(15):66. PubMed ID: 15373027
    [No Abstract]   [Full Text] [Related]  

  • 11. Drug approval system questioned in US and Canada.
    Eggertson L
    CMAJ; 2005 Feb; 172(3):317-8. PubMed ID: 15684107
    [No Abstract]   [Full Text] [Related]  

  • 12. Parecoxib, valdecoxib, and cardiovascular risk.
    Furberg CD; Psaty BM; FitzGerald GA
    Circulation; 2005 Jan; 111(3):249. PubMed ID: 15655125
    [No Abstract]   [Full Text] [Related]  

  • 13. Cyclooxygenase-2 inhibitors and cardiovascular risk.
    Smith ER
    Can J Cardiol; 2005 Mar; 21(3):307-8. PubMed ID: 15776124
    [No Abstract]   [Full Text] [Related]  

  • 14. Rationale for testing the cardiovascular risk for patients with COX-2 inhibitors on the basis of biomarker NT-proBNP.
    Giannitsis E
    Clin Lab; 2005; 51(1-2):63-83. PubMed ID: 15719708
    [TBL] [Abstract][Full Text] [Related]  

  • 15. COX-2 inhibitors--second, do some good.
    Harrison A
    N Z Med J; 2005 Apr; 118(1212):U1395. PubMed ID: 15806191
    [No Abstract]   [Full Text] [Related]  

  • 16. The Vioxx debacle revisited.
    Mohapatra PR; Janmeja AK
    Am J Med; 2005 Sep; 118(9):1058. PubMed ID: 16164909
    [No Abstract]   [Full Text] [Related]  

  • 17. [Cardiovascular risks of Cox-2-antagonists. Opinion on the marketed name rofecoxib, and its market-withdrawn valdecoxib and the actual therapeutic restrictions].
    Bolten WW; Reiter S;
    Z Rheumatol; 2005 May; 64(4):286-9. PubMed ID: 15909092
    [No Abstract]   [Full Text] [Related]  

  • 18. New restrictions on celecoxib (Celebrex) use and the withdrawal of valdecoxib (Bextra).
    Cotter J; Wooltorton E
    CMAJ; 2005 May; 172(10):1299. PubMed ID: 15833921
    [No Abstract]   [Full Text] [Related]  

  • 19. [Current EULAR data on valdecoxib. New study results of gastrointestinal safety and "cost effectiveness"].
    Kellner H
    Krankenpfl J; 2004; 42(5-6):185. PubMed ID: 15527245
    [No Abstract]   [Full Text] [Related]  

  • 20. Quantitative assessment of the gastrointestinal and cardiovascular risk-benefit of celecoxib compared to individual NSAIDs at the population level.
    Varas-Lorenzo C; Maguire A; Castellsague J; Perez-Gutthann S
    Pharmacoepidemiol Drug Saf; 2007 Apr; 16(4):366-76. PubMed ID: 16897817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.